Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 6Thoracic 4Gynecologic 3Head & Neck 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Genitourinary 1

Conditions

Neoplasms 1

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × seribantumab × Tumor-Agnostic × Clear all
NCT01447225 2016-09-14

Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

Merrimack Pharmaceuticals

Phase 1 Completed
43 enrolled 21 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡